Explain this page
Arphra AIPlain-English read on Halozyme Therapeutics, Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $88.25 (+26.98%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.74% | -2.92% | +0.42% | +9.17% | +11.72% | +3.27% | +28.89% | +110.80% | +60.29% | +682.66% | +1535.29% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$3.37M
9 txns
Net flow
−$3.37M
Aftermarket
LiveLast trade
$69.00
Bid
$68.00
2 sh
Ask
$71.20
100 sh
Spread
$3.200
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?zacks.com·Jun 10, 2026
- Anti-AI Investing: The HALO Moat Goes Off The Railsseekingalpha.com·Jun 09, 2026
- Sky Harbour: The Ultimate HALO Investment Taking Flightseekingalpha.com·Jun 07, 2026
- Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Upzacks.com·May 12, 2026
- HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCEprnewswire.com·May 11, 2026
- Halozyme to Report First Quarter 2026 Financial and Operating Resultsprnewswire.com·Apr 30, 2026
Recent analyst activity
DB- Jun 03, 2026GradeBuy → BuyBenchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on Near-Term PotentialUBS
- Jun 03, 2026PT$90.00Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on Near-Term PotentialUBS
Peers
No peer list available for HALO.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Torley Helen director, officer: PRESIDENT AND CEO | Sell | 1,500 | $101.51K | Jun 03, 2026 |
Torley Helen director, officer: PRESIDENT AND CEO | Sell | 400 | $26.55K | Jun 03, 2026 |
Torley Helen director, officer: PRESIDENT AND CEO | Sell | 2,000 | $137.47K | Jun 03, 2026 |
Torley Helen director, officer: PRESIDENT AND CEO | Sell | 6,100 | $425.12K | Jun 03, 2026 |
Torley Helen director, officer: PRESIDENT AND CEO | Sell | 16,600 | $1.1M | Jun 02, 2026 |
Torley Helen director, officer: PRESIDENT AND CEO | Sell | 3,400 | $226.93K | Jun 02, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|